[go: up one dir, main page]

PL3312177T3 - Związek tricyklicznej pochodnej, jego sposób wytwarzania i zawierająca go kompozycja farmaceutyczna - Google Patents

Związek tricyklicznej pochodnej, jego sposób wytwarzania i zawierająca go kompozycja farmaceutyczna

Info

Publication number
PL3312177T3
PL3312177T3 PL16807741T PL16807741T PL3312177T3 PL 3312177 T3 PL3312177 T3 PL 3312177T3 PL 16807741 T PL16807741 T PL 16807741T PL 16807741 T PL16807741 T PL 16807741T PL 3312177 T3 PL3312177 T3 PL 3312177T3
Authority
PL
Poland
Prior art keywords
same
pharmaceutical composition
derivative compound
tricyclic derivative
preparing
Prior art date
Application number
PL16807741T
Other languages
English (en)
Inventor
Hyunho Lee
Kwangwoo Chun
Bo-Young Joe
Eun Seon Kim
Eun Sung Jang
Hyeongchan OH
Jeong-Min Kim
Jiseon PARK
Hanchang LEE
Original Assignee
Onconic Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc. filed Critical Onconic Therapeutics Inc.
Publication of PL3312177T3 publication Critical patent/PL3312177T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16807741T 2015-06-09 2016-06-03 Związek tricyklicznej pochodnej, jego sposób wytwarzania i zawierająca go kompozycja farmaceutyczna PL3312177T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150081021 2015-06-09
PCT/KR2016/005911 WO2016200101A2 (ko) 2015-06-09 2016-06-03 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
EP16807741.0A EP3312177B1 (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
PL3312177T3 true PL3312177T3 (pl) 2021-11-02

Family

ID=57503424

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16807741T PL3312177T3 (pl) 2015-06-09 2016-06-03 Związek tricyklicznej pochodnej, jego sposób wytwarzania i zawierająca go kompozycja farmaceutyczna

Country Status (21)

Country Link
US (1) US10464919B2 (pl)
EP (1) EP3312177B1 (pl)
JP (2) JP2018521033A (pl)
KR (1) KR101837047B1 (pl)
CN (1) CN107849040B (pl)
AU (1) AU2016276806B9 (pl)
BR (1) BR112017026392B1 (pl)
CA (1) CA2990277C (pl)
CL (1) CL2017003138A1 (pl)
DK (1) DK3312177T3 (pl)
ES (1) ES2870203T3 (pl)
MX (1) MX375707B (pl)
MY (1) MY194590A (pl)
NZ (1) NZ738187A (pl)
PH (1) PH12017502228B1 (pl)
PL (1) PL3312177T3 (pl)
PT (1) PT3312177T (pl)
RU (1) RU2715413C2 (pl)
SA (1) SA517390509B1 (pl)
WO (1) WO2016200101A2 (pl)
ZA (1) ZA201708663B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36714A (es) 2015-06-09 2016-12-30 Bayer Pharma Akttiengesellschaft Moduladores alostéricos positivos del receptor muscarínico m2
MY194590A (en) * 2015-06-09 2022-12-05 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
WO2020155141A1 (zh) * 2019-02-02 2020-08-06 中国科学院上海有机化学研究所 治疗神经退行性疾病或rna结合蛋白发生异常导致的疾病的药物组合物及其应用
JP7707073B2 (ja) * 2019-04-09 2025-07-14 エフ. ホフマン-ラ ロシュ アーゲー モノアシルグリセロールリパーゼ(magl)の阻害剤としての複素環式化合物
BR112022000534A2 (pt) 2019-07-19 2022-05-10 Astrazeneca Ab Inibidores de parp1
AU2019459018A1 (en) * 2019-07-29 2022-02-17 Jeil Pharmaceutical Co.,Ltd Method for treating stroke by using tricyclic derivative
JP7702934B2 (ja) * 2019-08-14 2025-07-04 メトロ インターナショナル バイオテック,エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物
WO2021086133A1 (ko) * 2019-10-31 2021-05-06 (주)제이디바이오사이언스 삼환식 화합물 및 이의 약학적 용도
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
PE20231372A1 (es) 2020-09-03 2023-09-07 Hoffmann La Roche Compuestos heterociclicos
CA3216373A1 (en) * 2021-04-19 2022-10-27 Lynnie TRZOSS Parp1 inhibitors and uses thereof
MX2023012361A (es) * 2021-04-22 2023-10-31 Wigen Biomedicine Tech Shanghai Co Ltd Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
CN116710433A (zh) * 2021-04-23 2023-09-05 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
WO2022222995A1 (zh) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 吡啶酰胺类化合物
MX2023013624A (es) * 2021-05-18 2023-11-30 Onconic Therapeutics Inc Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma.
AU2022276986B2 (en) * 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
CN117769545A (zh) * 2021-08-05 2024-03-26 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
MX2024002425A (es) * 2021-08-27 2024-04-29 Impact Therapeutics Shanghai Inc Compuestos tricíclicos sustituidos como inhibidores de parp y uso de estos.
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023056039A1 (en) 2021-10-01 2023-04-06 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
WO2023122140A1 (en) * 2021-12-22 2023-06-29 Synnovation Therapeutics, Inc. Parp1 inhibitors
MX2024008771A (es) * 2022-01-13 2024-09-23 Acerand Therapeutics Hong Kong Ltd Derivado que contiene anillo de piperazino, su sal farmacéuticamente aceptable, su método de preparación y su aplicación.
IL320829A (en) 2022-01-21 2025-07-01 Xinthera Inc PARP1 inhibitors and their uses
KR20240162104A (ko) * 2022-03-11 2024-11-14 임팩트 테라퓨틱스 (상하이), 인코포레이티드 Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
EP4620472A3 (en) 2022-04-28 2025-10-01 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
US20250295642A1 (en) * 2022-05-07 2025-09-25 Medshine Discovery Inc. Fluoroquinoxalinone derivative for selectively inhibiting parp1
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
EP4617273A1 (en) * 2022-11-10 2025-09-17 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
PL2215075T3 (pl) * 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
MX2011004957A (es) 2008-11-11 2011-08-12 Je Il Pharmaceutical Co Ltd Nuevo derivado triciclico o las sales farmaceuticamente aceptables del mismo, metodo de preparacion del mismo, y composicion farmaceutica que contiene el mismo.
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
MY194590A (en) * 2015-06-09 2022-12-05 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법

Also Published As

Publication number Publication date
CN107849040B (zh) 2021-04-06
KR101837047B1 (ko) 2018-03-09
AU2016276806B9 (en) 2019-02-21
WO2016200101A3 (ko) 2017-02-02
AU2016276806B2 (en) 2019-02-14
JP6806969B2 (ja) 2021-01-06
CN107849040A (zh) 2018-03-27
JP2018521033A (ja) 2018-08-02
RU2715413C2 (ru) 2020-02-28
JP2019163287A (ja) 2019-09-26
RU2017146130A (ru) 2019-07-16
CL2017003138A1 (es) 2018-06-15
MX2017016013A (es) 2018-04-20
MX375707B (es) 2025-03-06
WO2016200101A2 (ko) 2016-12-15
US20180162834A1 (en) 2018-06-14
MY194590A (en) 2022-12-05
DK3312177T3 (da) 2021-07-05
ZA201708663B (en) 2019-04-24
PT3312177T (pt) 2021-05-17
PH12017502228B1 (en) 2022-08-03
EP3312177A4 (en) 2018-12-05
KR20160144916A (ko) 2016-12-19
PH12017502228A1 (en) 2018-06-11
SA517390509B1 (ar) 2021-06-02
US10464919B2 (en) 2019-11-05
NZ738187A (en) 2019-03-29
ES2870203T3 (es) 2021-10-26
EP3312177B1 (en) 2021-04-14
BR112017026392B1 (pt) 2023-12-26
CA2990277A1 (en) 2016-12-15
EP3312177A2 (en) 2018-04-25
AU2016276806A1 (en) 2018-01-04
RU2017146130A3 (pl) 2019-07-17
CA2990277C (en) 2021-10-26
BR112017026392A2 (pl) 2018-08-21

Similar Documents

Publication Publication Date Title
ZA201708663B (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
PL3453707T3 (pl) Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
PT3643709T (pt) Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
PT3339294T (pt) Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl
EP3153165A4 (en) Rapamycin derivative, preparation method therefor, and pharmaceutical composition and uses thereof
IL256686A (en) Preparation method for lyophilized pharmaceutical preparations and pharmaceutical preparations prepared in this way
EP3199541A4 (en) Cyclic peptide derivative, method for preparing same and composition thereof
EP3181553A4 (en) Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
EP3284743A4 (en) Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof
PL3391893T3 (pl) Kompozycja farmaceutyczna do leczenia białaczki i sposób jej przygotowania
IL251456A0 (en) Substances with agonist activity for gpr119, processes for their preparation and preparations containing them
SI3303320T1 (sl) Nove heterociklične spojine, postopek za pripravo le-teh in farmacevtski sestavek vsebujoč le-te
IL267914B (en) History of monoterpene phenol, process for their preparation and pharmaceutical preparations containing them
ZA201908090B (en) Pharmaceutical composition and method for preparing same
HUE059610T2 (hu) Gyógyszerészeti készítmény, amely indolszármazékokat tartalmaz, valamint eljárás annak elõállítására és felhasználására
ZA201804391B (en) Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same
EP3138830A4 (en) Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same
TWI562978B (en) Method for preparation of 1,4-cyclohexanedialkanol
PL3061765T3 (pl) Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek